## REVIEW



# Endocuff-assisted versus standard colonoscopy for improving adenoma detection rate: meta-analysis of randomized controlled trials

J. Wang<sup>1</sup>  $\cdot$  C. Ye<sup>1</sup>  $\cdot$  S. Fei<sup>1</sup>

Received: 25 October 2021 / Accepted: 18 May 2022 / Published online: 2 August 2022 © Springer Nature Switzerland AG 2022

## Abstract

**Background** The effect of Endocuff-assisted colonoscopy compared with standard colonoscopy is conflicting in terms of the adenoma detection rate. The aim of this meta-analysis was to compare the efficacy of Endocuff-assisted colonoscopy for adenoma detection.

**Methods** PubMed, Embase, Google Scholar and Cochrane Library were searched up to the end of June 8, 2021. All randomized controlled trials (RCTs) comparing Endocuff-assisted colonoscopy with standard colonoscopy were included. Dichotomous data were pooled to obtain the relative risk with a 95% CI, whereas continuous data were pooled using a mean difference with 95% CI.

**Results** A total of 23 RCTs involving 17,999 patients were included. Compared with standard colonoscopy, use of the Endocuff was associated with a significant improvement in the adenoma detection rate (RR = 1.16, 95% CI 1.08–1.24), polyp detection rate (RR = 1.17, 95% CI 1.09–1.25), sessile serrated lesion detection rate (RR = 1.23, 95% CI 1.05–1.43), left-side lesion detection rate (RR = 1.24, 95% CI 1.08–1.43), and mean number of adenomas per patient (MD = 0.17, 95% CI 0.08–0.26). There were no significant differences between the and groups in detection of advanced adenomas, mean number of polyps per patient, right-side lesion detection rate, cecal intubation rate, cecal intubation time and withdrawal time. **Conclusions** The pooled evidence suggests a significant improvement in the adenoma detection rate, and polyp detection rate using the Endocuff. On the other hand, no significant effect on the detection of advanced adenomas and mean number of polyps per patient was noted.

Keywords Colonoscopy · Endocuff · Adenoma detection · Meta-analysis

# Introduction

Globally, colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer death [1]. Morbidity and mortality associated with CRC can be mitigated through appropriate screening and surveillance. Colonoscopy, as a screening procedure, is a gold standard in detecting tumors at an earlier and more treatable stage and also facilitates the timely removal of precancerous lesions or adenomas [2]. The adenoma detection

Jun Wang, Chuncui Ye contributed equally to this work.

S. Fei jsxzfsj99@163.com

rate (ADR) is now the main quality indicator of colonoscopy because of its inverse correlation with interval cancer rate [3, 4]. ADR can be improved by technique or devices that improve mucosal exposure or by tools that highlight flat colonic lesions.

A number of distal attachments have been tested to improve ADR, including a transparent cap, cuff, or rings [5]. The cuff is attached to the tip of the colonoscope, and the fingers are used to flatten colonic folds, leading to increased mucosal visualization [6]. Endocuff (Arc Medical, Leeds, UK), which was granted United States Food and Drug Administration approval in 2012, is a soft plastic cap with rows of finger-like projections attached onto the colonoscope tip. In 2014, the next-generation Endocuff (Endocuff Vision) was released, consisting of a single row of finger-like projections which were 3 mm longer [7].

A number of studies have been published comparing the efficacy of Endocuff-assisted colonoscopy (EAC) to that of

<sup>&</sup>lt;sup>1</sup> Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou 221002, Jiangsu, People's Republic of China

standard colonoscopy, but so far, the impact of EAC on ADR is conflicting with data suggesting equivocal benefit from its use. Aside from individual studies, several meta-analyses have been performed to assess the effect of Endocuff [8–12]. Fewer randomized controlled trials (RCTs) were included in the early meta-analyses, and the high heterogeneity noted called for careful interpretation of the results. The most recent meta-analysis [12], including 8 RCTs, found a significant improvement in ADR and mean number of adenomas per colonoscopy with shorter withdrawal times using the second-generation cuff device compared with standard colonoscopy have recently been published [13–18]. Therefore, we conducted a meta-analysis of published data to evaluate the efficacy and safety of EAC.

# **Materials and methods**

This systematic review and meta-analysis have been registered at NIHR PROSPERO (CRD42021231865). It is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19].

# Search strategy

A literature search was conducted using PubMed, Embase, Google Scholar and Cochrane Library up to June 8, 2021 without language restrictions. Relevant studies were identified using the following terms: "Endocuff", "Endocuff vision", "distal attachment" and "adenoma detection rate or ADR". The search was restricted to human subjects. Additional studies were identified using a hand search of references of original or review articles and international conferences on this topic, primarily including United European Gastroenterology Week (UEGW) and Digestive Disease Week (DDW).

## Inclusion and exclusion criteria

Studies were included if they met the following criteria: (1) RCTs that compared Endocuff-assisted and standard colonoscopy for adenoma detection, (2) presenting the detailed outcomes of Endocuff-assisted and standard colonoscopy or including such data for calculation in the article. Non-randomized prospective, retrospective, feasibility or pilot studies, meta-analysis, editorials, reviews, case reports/series, studies not reporting on ADR and duplicate publications were excluded.

#### **Data extraction**

Two investigators (Wang J, Ye C) independently extracted the data and reached a consensus for all items. If the investigators generated different results, they checked the data again and had a discussion to reach an agreement. If they were unable to reach an agreement, an expert (Fei S) was invited to join the discussion. Data extracted from the selected articles included the first author's name, year of publication, country of origin, study period, device type, indications for colonoscopy, baseline characteristic of the patients, and primary outcomes.

## **Bias assessment**

The risk of bias in individual studies was assessed using the Cochrane Collaboration tool [20]. This particular tool evaluates different domains of potential source of bias: random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. The analysis results were defined as low, high or unclear bias (bias-related information is not clear or bias cannot be determined). Publication bias was assessed using subjective judgment based on funnel plots as well quantitatively using Egger's regression analysis. A p value < 0.05 was indicative of substantial publication bias.

## **Outcome measures**

The primary outcome of this study was to calculate a pooled ADR. The secondary outcomes were the polyp detection rate, detection rate of advanced adenomas, sessile serrated lesion detection rate, mean number of adenomas per patient, mean number of polyps per patient right-sided lesion detection rate, left-sided lesion detection rate, ileum intubation rate, cecal intubation rate, cecal intubation time, withdrawal time, and adverse events.

## **Statistical analysis**

A meta-analysis was performed using the Cochrane Collaboration RevMan 5.4 and STATA package version 12.0. The analyses were performed by calculating pooled estimates of primary and secondary outcome. Relative risk (RR) with 95% confidence interval (CI) for each proportional outcome was calculated. Mean difference (MD) with 95% CI was calculated for continuous variables. The  $\chi^2$ -test-based Q statistic test was performed to assess the between-study heterogeneity. We also quantified the effect heterogeneity according to the  $I^2$  test. When a significant Q test (P < 0.05) or  $I^2 > 50\%$  indicated heterogeneity across studies, the random effects model was used; otherwise, the fixed effects model was used. An analysis of sensitivity was performed to evaluate the stability of the results. Additionally, we conducted subgroup analysis by the ADR for standard colonoscopy groups (baseline ADR), the device type (Endocuff or Endocuff Vision), adenoma size ( $\leq 5$  mm, 6-9 mm,  $\geq 10$  mm) and indications for endoscopy (screening or mixed population). A p value of < 0.05 was regarded as being statistically significant.

# Results

## **Study characteristics**

Following the searching strategy, a total of 546 citations were identified. According to the inclusion criteria, 25 studies were selected and subjected to further examination [13–18, 21–39]. We excluded 2 studies [38, 39] because they are randomized tandem studies. Therefore, 23 RCTs with 17,999 patients were included in the

meta-analysis [13–18, 21–37]. (Fig. 1). The characteristics of the selected studies are summarized in Table 1. Of the 23 eligible studies, 5 were from the United States [14, 23, 24, 28, 33], 3 each from United Kingdom [15, 21, 31] and Germany [22, 26, 36], 2 from mixed countries [13, 32], 2 from Thailand [17, 35], and 1 each from Spain [16], Italy [18], Portugal [25], Mexico [27], Australia [29], France [30], Netherlands [34], and Japan [37]; Nine studies were multicenter [15, 16, 18, 23, 24, 26, 31, 32, 34], 4 were two-center [13, 22, 33, 37] and 10 were single-center experiences [14, 17, 21, 25, 27-30, 35, 36]. All studies were published in English (18 full-text articles [13–18, 21, 22, 26, 27, 29–34, 36, 37] and 5 abstracts [23–25, 28, 35]). Eleven studies used the first-generation Endocuff [13, 14, 22-24, 26-28, 32, 34, 37], and 12 studies used the second-generation device (Endocuff Vision) [15-18, 21, 25, 29-31, 33, 35, 36].

Risk of bias assessment using the Cochrane Collaboration tool is provided in supplementary table 1 and supplementary Fig. 1 (Fig.S1). The shape of the funnel plots did not reveal any evidence of asymmetry (Fig. S2). Egger's test also showed no statistical significance in evaluation of publication bias (p = 0.427).



Table 1 Characteristics	of the included stu-	dies										
Study	Country	Year	Study period	Device	Indications	Center	Numb patien	er ts	Age, ye	ars G	ender nen %)	Primary outcome
							EAC	SC	EAC	SC E	AC SC	
Aniwan et al. [17]	Thailand	2021	2019-2020	Endocuff Vision	Screening	1	250	250	61.1	51.1 3	4.4 33.	2 ADR
Bhattacharyya et al. [21]	UK	2017	2015-2016	Endocuff Vision	Positive FOBT, Polyp surveillance	1	266	265	68	57 6	.79 67.	MPP (
Biecker et al. [22]	Germany	2014	2013.2–2013.8	Endocuff	Colorectal cancer screening, follow-up examination, evalu- ation for anemia, or abdominal pain	7	245	253	65	58	8.2 51.	8 Number of polyps per colonoscopy
Catalano et al. [23]	USA	2017	NA	Endocuff	Screening	Multi-center	809	764	NA	Z	N.	ADR
Cattau et al. [24]	NSA	2015	2015.1-2015.5	Endocuff	Screening	3	329	329	58*	4	8.2*	ADR
Costa Santos et al. [25]	Portugal	2019	2018–2019	Endocuff Vision	NA	1	81	89	62.4*	ίΩ.	7.4*	Mean sessile serrated lesion per colonpscopy
Floer et al. [26]	Germany	2014	2014.2–2014.7	Endocuff	Screening, surveil- lance or diagnostic colonoscopy (anemia or abdominal dis- comfort)	4	249	243	64	63	44	) ADR
Floer et al. [13]	Germany/Poland	2020	2015.1-2017.12	Endocuff	Screening, diagnostic colonoscopy and follow-up examina- tion	7	189	195	62	63 4	9.7 45.	ó ADR
González-Fernández et al. [27]	Mexico	2017	2014–2015	Endocuff	Screening	1	174	163	60	62	9 24	ADR
Hass et al. [28]	USA	2016	NA	Endocuff	Screening, surveil- lance, bright red blood per rectum, constipation and abdominal pain	-	281	281	AN	N AN	A NA	NA
Jacob et al. [29]	Australia	2019	2016-2017	Endocuff Vision	NA	1	182	138	NA	NA 5	5.7 59.	3 ADR
Karsenti et al. [30]	France	2020	2017–2018	Endocuff Vision	Screening, history of polyp/cancer, FIT+, digestive symptoms	1	1026	1032	59.25	57.4 4	7.4 49	ADR
Marsano et al. [14]	USA	2019	2016.3-2017.1	Endocuff	Screening, surveillance	1	42	42	09	59.3 5	4.8 54.	8 ADR
Ngu et al. [31]	UK	2019	2014-2016	Endocuff Vision	BCSP, BCSP surveil- lance, colonoscopy conversion from bowel scope, sympto- matic diagnostic, symptomatic surveil- lance	٢	888	884	61.7	62.1 5	7.1 56.	3 ADR

Table 1 (continued)												
Study	Country	Year	Study period	Device	Indications	Center	Numb	er ts	Age, yea	rs Gen (me	ider n %)	Primary outcome
							EAC	SC	EAC S	C EA(	C SC	
Rees et al. [15]	UK	2020	2017-2018	Endocuff Vision	Screening	16	1610	1612	55 5	5 53	53	ADR
Rex et al. [32]	USA/Italy	2018	NA	Endocuff	Screening, surveil- lance, diagnostic	en	299	295	63.2 6	2.6 53	53	APC
Rex et al. [33]	USA	2020	2017-2018	Endocuff Vision	Screening, surveillance	2	101	66	62.7 6	1.7 56.4	42.4	Withdrawal time
Rivero-Sánchez et al. [16]	Spain	2019	2015–2017	Endocuff Vision	Surveillance after the complete removal of all serrated lesions 4 mm and adenomas	4	62	60	61.2 6	0.2 68	52	Mean number of serrated lesions per patient
van Doorn et al. [34]	Netherlands	2015	2013–2014	Endocuff	Polyp surveillance, symotons, positive family history, FIT+ screening	2	530	533	65 6	5 50	54	MAP
Vanduangden et al. [35]	Thailand	2020	NA	Endocuff Vision	Screening	1	200	204	NA 1	IA NA	NA	ADR
von Figura et al. [36]	Germany	2019	Υ	Endocuff Vision	Screening, grounds to suspect tumor, abdominal com- plaints, Surveillance after colorectal can- cer, gastrointestinal bleeding or anemia, history of colorectal polyps, suspected inflammatory process	_	118	122	63.6	5.3 51.7	62.3	The average duration of polypectomy
Wada et al. [37]	Japan	2018	2015.4–2015.9	Endocuff	Screening, polyp sur- veillance, symptoms, gastrointestinal bleeding, positive fecal occult blood test result	6	239	238	61.2 €	2.2 51	48.3	ADR, MAP
Zorzi et al. [18]	Italy	2021		Endocuff Vision	FIT+ screening	13	908	905	60.2 6	0.1 53.7	7 53.8	ADR
FIT fecal immunochen	nical testing, BCS	P Bowel	Cancer Screening	g Programme, ADR	adenoma detection rate,	MAP mean n	umber o	f adenc	mas per	patient,	MPP me	an polyp per patient, APC

adenomas per colonoscopy, NA not available

#### **Quantitative data synthesis**

#### **Primary outcome**

Adenoma detection rate All 23 studies reported ADR in the Endocuff and standard colonoscopy groups. The pooled ADR was 44.9% (95% CI 37.6–52.1) for EAC and 39.1% (95% CI 32.3–45.9) for standard colonoscopy. The pooled RR was 1.16 (95% CI 1.08–1.24, p <0.00001) (Fig. 2; Table 2).

In subgroup analyses based on the ADR in the standard colonoscopy group, a significant difference was observed between Endocuff and standard colonoscopy groups (baseline ADR < 25%: RR = 1.47, 95% CI 1.13–1.93, p=0.004; baseline ADR < 30%: RR = 1.39, 95% CI 1.21–1.58, p < 0.00001; baseline ADR < 35%: RR = 1.40, 95% CI 1.25–1.58, p=0.03; baseline ADR < 40%: RR = 1.37, 95% CI 1.23–1.52, p=0.004; baseline ADR < 45%: RR = 1.28, 95% CI 1.15–1.41, p < 0.0001; baseline ADR < 50%: RR = 1.24, 95% CI 1.13–1.36, p < 0.0001). In contrast, no statistical difference was found in the subgroup of baseline ADR > 50% (RR = 1.04, 95% CI 0.97–1.11, p=0.50) (Table 2).

Eight studies reported adenoma size. The pooled results showed ADR did not differ between Endocuff and standard colonoscopy (size  $\geq$  10 mm: RR = 1.02, 95% CI 0.91–1.15, p=0.47; 6–9 mm: RR = 1.10, 95% CI 0.96–1.27, p=0.29; size  $\leq$  5 mm: RR = 1.03, 95% CI 0.95–1.11, p=0.05) (Table 2).

In the subgroup analysis of device type, a significant difference was found in both subgroups (Endocuff: RR = 1.22, 95% CI 1.07–1.40, p < 0.00001; Endocuff Vision: RR = 1.12, 95% CI 1.05–1.20, p = 0.11) (Table 2).

When grouping by indications for colonoscopy (pure screening or mixed populations), a significant difference was found in both subgroups (pure screening: RR = 1.20, 95% CI 1.06–1.37, p = 0.001; mixed population: RR = 1.14, 95% CI 1.05–1.23, p = 0.0007) (Table 2).

#### Secondary outcome

**Polyp detection rate** 13 studies with 11,421 patients reported polyp detection rates. The pooled polyp detection rate in the Endocuff group was 54.5% (95% CI 44.6–64.4) and in the standard colonoscopy group was 46.5% (95% CI 37.2–55.9). The pooled RR was 1.17 (95% CI 1.09–1.25, p=0.0008) (Fig. 3; Table 2).

Sessile serrated lesion detection rate Ten studies with 9914 patients reported Serrated polyp detection rates. The pooled serrated detection rate was 8.4% (95% CI 5.8–11.1) for Endocuff and 5.9% (95% CI 4.0–7.8) for standard colonoscopy. The pooled RR was 1.23 (95% CI 1.05–1.43, p=0.46) (Fig. 3; Table 2).

**Detection rate of advanced adenomas** Seven studies with 9243 patients reported Advanced ADR. The pooled Advanced ADR was 13.7% (95% CI 8.0–19.4) for Endocuff and 12.7% (95% CI 7.3–18.1) for standard colonoscopy. The

	Endoc	uff	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Aniwan 2021	129	250	119	250	5.0%	1.08 [0.91, 1.29]	_ <b>+•</b>
Bhattacharyya 2017	162	266	167	265	5.9%	0.97 [0.85, 1.10]	
Biecker 2014	87	240	69	249	3.5%	1.31 [1.01, 1.70]	
Catalano 2017	273	809	154	764	5.1%	1.67 [1.41, 1.99]	
Cattau 2015	164	329	153	329	5.3%	1.07 [0.91, 1.26]	
Costa Santos 2019	58	81	60	89	4.6%	1.06 [0.87, 1.30]	<del></del>
Floer 2014	87	249	50	243	3.0%	1.70 [1.26, 2.29]	
Floer 2020	60	189	59	195	3.0%	1.05 [0.78, 1.41]	
González-Fernández 2017	39	174	22	163	1.6%	1.66 [1.03, 2.68]	
Hass 2016	119	281	126	281	4.8%	0.94 [0.78, 1.14]	
Jacob 2019	67	182	40	138	2.7%	1.27 [0.92, 1.75]	
Karsenti 2020	402	1026	304	1032	6.1%	1.33 [1.18, 1.50]	
Marsano 2019	23	42	22	42	2.1%	1.05 [0.70, 1.56]	
Ngu 2019	363	888	320	884	6.2%	1.13 [1.00, 1.27]	
Rees 2020	209	1578	193	1578	4.9%	1.08 [0.90, 1.30]	
Rex 2018	191	299	166	295	5.9%	1.14 [0.99, 1.30]	
Rex 2020	62	101	52	99	3.8%	1.17 [0.92, 1.49]	
Rivero-Sánchez 2019	26	62	20	60	1.6%	1.26 [0.79, 2.00]	
van Doorn 2015	275	530	278	533	6.2%	0.99 [0.89, 1.12]	-+-
Vanduangden 2020	106	200	99	204	4.7%	1.09 [0.90, 1.32]	<del></del>
von Figura 2019	45	118	52	122	2.9%	0.89 [0.66, 1.22]	
Wada 2018	134	239	93	238	4.6%	1.43 [1.18, 1.74]	
Zorzi 2021	434	908	369	905	6.5%	1.17 [1.06, 1.30]	
Total (95% CI)		9041		8958	100.0%	1.16 [1.08, 1.24]	•
Total events	3515		2987				
Heterogeneity: Tau <sup>2</sup> = 0.02; 0	>hi² = 63.	06, df=	22 (P < 0	0.00001	1); I <sup>2</sup> = 65'	% —	
Test for overall effect: Z = 4.3	4 (P < 0.0	1001)	-				U.S U./ 1 1.S Z
							Favours (Standard) Favours (Endocum)

Fig. 2 Forest plots comparing endoscopic-assisted and standard colonoscopy in terms of ADR. ADR adenoma detection rate

Table 2Outcomes of meta-<br/>analysis comparing EAC and<br/>SC

Outcomes	No.	EAC %	SC %	RR (95% CI)	р	$I^2$
ADR	23	44.9 (37.6–52.1)	39.1 (32.3–45.9)	1.16 (1.08–1.24)	< 0.00001	65%
Device						
Endocuff	11	43.3 (35.9–50.6)	36.3 (27.1-45.6)	1.22 (1.07-1.40)	< 0.00001	78%
Enducuff Vision	12	46.3 (35.0–57.6)	41.7 (31.5–51.9)	1.12 (1.05-1.20)	0.11	35%
Indication						
Screening	7	38.7 (24.3–53.1)	32.6 (20.5-44.7)	1.20 (1.06, 1.37)	0.001	73%
Mixed	16	47.4 (42.1–52.8)	42 (35.6–48.4)	1.14 (1.05, 1.23)	0.0007	61%
Baseline ADR						
< 50%	17	39.4 (31.8–46.9)	32.9 (26.4–39.4)	1.24 (1.13, 1.36)	< 0.0001	70%
> 50%	6	60.7 (54.7-66.8)	57.2 (52.2–62.3)	1.04 (0.97, 1.11)	0.50	0
Size						
≥ 10 mm	7	11.7 (8.2–15.1)	11.2 (7.9–14.6)	1.02 (0.91, 1.15)	0.47	0
6–9 mm	4	15 (10.9–19.1)	13.8 (8.6–18.9)	1.10 (0.96, 1.27)	0.29	20%
$\leq 5 \text{ mm}$	5	50 (25-75)	49.9 (24.2–75.7)	1.03 (0.95, 1.11)	0.05	59%
PDR	13	54.5 (44.6-64.4)	46.5 (37.2–55.9)	1.17 (1.09–1.25)	0.0008	64%
AADR	7	13.7 (8.0–19.4)	12.7 (7.3–18.1)	1.11 (1.00–1.23)	0.45	0
SDR	10	8.4 (5.8–11.1)	5.9 (4.0-7.8)	1.23 (1.05–1.43)	0.46	0
LDR	6	30.5 (22.7–38.4)	25.5 (17.6–33.4)	1.24 (1.08–1.43)	0.08	43%
RDR	9	28.7 (23.3–34)	25.2 (19.7-30.7)	1.21 (1.00–1.46)	< 0.00001	83%
Ileal intubation rate	7	61 (43.6–78.5)	68 (50.9-85)	0.89 (0.80-0.99)	0.0001	78%
Cecal intubation rate	8	97.4 (96.7–98.2)	96.9 (95.4–98.3)	1.00 (1.00-1.01)	0.29	18%
Adverse events	16	_	-	2.6 (1.29-5.26)	0.01	51%
				MD (95% CI)	р	$I^2$
MAP	10	_	-	0.17 (0.08-0.26)	< 0.00001	78%
MPP	4	_	_	0.16 (0-0.32)	< 0.00001	93%
Withdrawal time	8	-	-	- 0.29 (- 0.91, 0.33)	0.004	66%
Cecal intubation time	5	-	-	-0.60(-1.45, 0.26)	0.002	77%

*EAC* endocuff-assisted colonoscopy, *SC* standard colonoscopy, *RR* relative risk, *CI* confidence interval, *MD* mean difference, *ADR* adenoma detection rate, *PDR* polyp detection rate, *AADR* advanced ADR, *SDR* sessile serrated lesion detection rate, *RDR* right-side lesion detection rate, *LDR* left-side lesion detection rate, *MAP* mean number of adenomas per patient, *MPP* mean number of polyps per patient Bold indicates a meaningful result

pooled RR was 1.11 (95% CI 1.00–1.23, p = 0.45) (Fig. S3; Table 2).

**Right and left-side lesion detection rate** The right- and leftsided lesion detection rates were reported in 9 and 6 studies, respectively. The pooled right-sided lesion detection rate was 28.7% (95% CI 23.3–34) for Endocuff and 25.2% (95% CI 19.7–30.7) for standard colonoscopy. The pooled RR was 1.21 (95% CI 1.00–1.46, p < 0.00001) (Table 2). The pooled left-sided lesion detection rate was 30.5% (95% CI 22.7–38.4) for Endocuff and 25.5% (95% CI 17.6–33.4) for standard colonoscopy. The pooled RR was 1.24 (95% CI 1.08–1.43, p=0.08) (Fig. 3; Table 2).

Mean number of adenomas per patient Ten studies with 10,178 patients reported the available data between Endo-

cuff and standard colonoscopy and the pooled mean difference with a random-effect model were 0.17 (95% CI 0.08–0.26, p < 0.00001) (Fig. 4; Table 2). The results above indicate a significant difference between the two groups.

## Adverse events

Sixteen studies reported the available data between Endocuff and standard colonoscopy. The most commonly reported complication was minor mucosal lacerations, which was reported in 66 patients in Endocuff group (4%), and in 7 patients in Endocuff Vision group (0.1%). The other complication was loss of Endocuff (0.4%), post-polypectomy bleeding (0.3%), bleeding (0.06%), and perforations (0.04%). The pooled RR with a random effects model was 2.60 (95% CI: Α

	Endoc	uff	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bhattacharyya 2017	187	266	185	265	10.0%	1.01 [0.90, 1.13]	-
Biecker 2014	138	245	106	253	6.8%	1.34 [1.12, 1.61]	
Floer 2014	138	249	93	243	6.4%	1.45 [1.19, 1.76]	
Floer 2020	98	189	92	195	6.1%	1.10 [0.90, 1.35]	
González-Fernández 2017	52	174	26	163	2.2%	1.87 [1.23, 2.85]	
Hass 2016	177	281	167	281	9.0%	1.06 [0.93, 1.21]	
Jacob 2019	97	182	48	138	4.4%	1.53 [1.17, 2.00]	
Karsenti 2020	474	1026	389	1032	10.4%	1.23 [1.11, 1.36]	
Ngu 2019	480	888	424	884	10.9%	1.13 [1.03, 1.24]	
Rees 2020	451	1578	420	1578	9.9%	1.07 [0.96, 1.20]	+
Rex 2018	247	299	226	295	11.4%	1.08 [0.99, 1.17]	
von Figura 2019	64	118	64	122	5.1%	1.03 [0.82, 1.31]	
Wada 2018	150	239	117	238	7.6%	1.28 [1.09, 1.50]	
Total (95% CI)		5734		5687	100.0%	1.17 [1.09, 1.25]	◆
Total events	2753		2357				
Heterogeneity: Tau <sup>2</sup> = 0.01; 0	chi² = 33.	52, df=	12(P = 0	).0008)	; I <sup>2</sup> = 64%	, —	
Test for overall effect: Z = 4.5	9 (P < 0.0	0001)					U.S U./ 1 1.S Z
							Favours (Standard) Favours (Endocum)

В							
	Endoc	uff	Stand	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	CI M-H, Fixed, 95% CI
Aniwan 2021	2	250	2	250	0.8%	1.00 [0.14, 7.04]	4]
Costa Santos 2019	7	81	2	89	0.8%	3.85 [0.82, 17.98]	3]
Hass 2016	31	281	25	281	10.6%	1.24 [0.75, 2.04]	4]
Marsano 2019	10	42	7	42	3.0%	1.43 [0.60, 3.40]	]
Ngu 2019	20	888	10	884	4.2%	1.99 [0.94, 4.23]	3]
Rees 2020	5	1578	4	1578	1.7%	1.25 [0.34, 4.65]	5]
Rex 2018	33	299	36	295	15.4%	0.90 [0.58, 1.41]	I] —
Rex 2020	20	101	11	99	4.7%	1.78 [0.90, 3.52]	2]
van Doorn 2015	144	530	130	533	54.9%	1.11 [0.91, 1.37]	r] – <mark>–</mark> –
Zorzi 2021	17	908	9	905	3.8%	1.88 [0.84, 4.20]	
Total (95% CI)		4958		4956	100.0%	1.23 [1.05, 1.43]	▶
Total events	289		236				
Heterogeneity: Chi <sup>2</sup> =	8.77, df=	9 (P =	0.46); I <sup>z</sup> =	:0%			
Test for overall effect: .	Z = 2.56 (	(P = 0.0	1)				0.05 0.2 1 5 20 Favours [Standard] Favours [Endocuff]

С

	Endoc	uff	Standa	ard		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Aniwan 2021	77	250	78	250	16.3%	0.99 [0.76, 1.28]	
Jacob 2019	44	182	18	138	6.4%	1.85 [1.12, 3.06]	
Karsenti 2020	184	1026	123	1032	20.5%	1.50 [1.22, 1.86]	<b>-</b>
Marsano 2019	10	42	11	42	3.2%	0.91 [0.43, 1.91]	
Ngu 2019	232	888	196	884	25.1%	1.18 [1.00, 1.39]	<b>⊢</b> ∎−−
Zorzi 2021	322	908	260	905	28.5%	1.23 [1.08, 1.41]	
Total (95% CI)		3296		3251	100.0%	1.24 [1.08, 1.43]	◆
Total events	869		686				
Heterogeneity: Tau <sup>2</sup> =	0.01; Ch	i <sup>z</sup> = 9.71	D, df = 5 (	P = 0.0	8); I <sup>2</sup> = 48	% -	
Test for overall effect:	Z = 3.10	(P = 0.0	102)				Favours [Standard] Favours [Endocuff]

Fig. 3 Forest plots comparing endoscopic-assisted and standard colonoscopy in terms of second outcomes. A Polyp detection rate; B Serrated lesion detection rate, C left-sided lesion detection rate

1.29–5.26, p = 0.01) (Table 2). Stratification based on device type, similar results were observed in the Endocuff group (77/1536, RR = 7.16, 95% CI 3.82–13.41, p = 0.09), but not in the Endocuff Vision group (31/5241, RR = 1.31, 95% CI 0.78–2.20, p = 0.50) (Fig. S4).

#### Other outcomes

For additional secondary outcomes, including ileum intubation rate, MPP, cecal intubation rate, cecal intubation time, and withdrawal time, there was no significant difference between the two groups except for ileum intubation rate (61% versus 68%, RR = 0.89, 95% CI 0.80–0.99, p = 0.0001) (Fig. S5; Table 2).



Fig. 4 Forest plots comparing endoscopic-assisted and standard colonoscopy in terms of MAP. MAP mean number of adenomas per patient

# Discussion

In this study, we included 23 studies involving 17,999 patients to assess the efficacy and safety of the EAC for ADR. The results showed that the EAC was superior to standard colonoscopy in terms of adenoma, polyp, sessile serrated, and left and right-sided lesion detection rates as well as mean number of adenomas per patient. No significant difference was found in advanced ADR, mean number of polyps per patient, right-sided lesion detection rates, cecal intubation rate, cecal intubation time and withdrawal time between EAC and standard colonoscopy.

Colonoscopy with adenoma detection and removal is widely considered the gold standard for the prevention of CRC. Every 1% increase in ADR is associated with a 3% reduction of interval CRC and 5% reduction of fatal interval CRC. Moreover, there is an increased risk of interval cancer when the colonoscopy is performed by an endoscopist with an ADR below 20% [3]. Recent years have seen the rapid introduction of a range of new mechanical and optical endoscopic devices aimed at improving the ADR and minimizing miss rates [40–43].

Due to the use of different devices, we further analyzed the efficacy of Endocuff or Endocuff Vision separately, and the pooled result indicated significant differences in both groups, which was in accordance with a previous study [12]. Moreover, the pooled ADR was slightly higher in the Endocuff Vision group (46.3%) compared with the Endocuff group (43.3%). However, a recent meta-analysis conducted by Aziz et al. [44], evaluated colonoscopy outcomes among Endocuff Vision, Endocuff and high-definition colonoscopy groups, and reported that the Endocuff Vision did not significantly improve ADR compared to Endocuff and high-definition colonoscopy. Because of the different expertise of endoscopists, we conducted subgroup analysis for ADR based on ADR in standard colonoscopy group (< 25%, <30%, <35%, <40%, <45%, <50% and >50%). The results showed that operators with baseline ADR < 50% benefit from the use of EAC, whereas the very high baseline detectors (ADR > 50%) did not. Hence, it is clearly suggested that the expertise of the endoscopist is inversely correlated with the benefit of Endocuff in terms of ADR vs. standard colonoscopy.

In addition, we performed subgroup analysis for ADR based on indications for colonoscopy, which indicated significant differences in both groups. A higher ADR was observed in mixed population (47.4% vs 38.7% in screening group). More studies including pure screening population are needed to further confirm the effect of population on ADR. As for colorectal adenomas size, up to 15.5% of small adenomas and up to 3.4% of diminutive adenomas contain high-grade dysplasia, and the omission of those adenomas may contribute to the occurrence of interval cancers diagnosed between surveillance colonoscopies [45]. In this study, we also conducted subgroup analysis based on adenomas size and no significant difference was found. However, because only a few studies were included in the above analysis, the result should be interpreted with caution, and more studies are needed. With regard to adverse events, the results showed that the rate in the first-generation Endocuff, rather than the second-generation Endocuff Vision, was higher than in standard colonoscopy. The revised design of the Endocuff, with the removal of the distal row of arms and the creation of more rounded tips, might explain the absence of the adverse events.

Some limitations of this meta-analysis should be addressed. First, the quality of bowel preparation was reported incompletely using different scoring criteria in the included studies. Second, the endoscopists in both groups were not blinded, which is common to most endoscopic studies designed for assessment of external attachments. Third, we did not perform a comparative cost-effectiveness analysis. Ideally, adoption of interventions in clinical practice would be premised on incremental cost with each intervention per additional adenoma detected.

## Conclusions

This meta-analysis showed that a significant improvement in adenoma and polyp detection rates as well as mean number of adenomas per patient using EAC compared with standard colonoscopy, especially for operators with a low ADR. Further studies are needed to confirm the value of Endocuff in improving the ADR.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10151-022-02642-9.

## Declarations

**Conflict of interest** Jun Wang, Chuncui Ye, and Sujuan Fei have no conflicts of interest or financial ties to disclose.

# References

- Keum N, Giovannucci E (2019) Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 16:713–732
- Winawer SJ, Zauber AG, Ho MN (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981
- Kaminski MF, Thomas-Gibson S, Bugajski M (2017) Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. Endoscopy 49:378–397
- Corley DA, Jensen CD, Marks AR (2014) Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 370:1298–1306
- 5. Gkolfakis P, Tziatzios G, Spartalis E (2018) Colonoscopy attachments for the detection of precancerous lesions during colonoscopy: a review of the literature. World J Gastroenterol 24:4243–4253
- Tsiamoulos ZP, Misra R, Rameshshanker R (2018) Impact of a new distal attachment on colonoscopy performance in an academic screening center. Gastrointest Endosc 87:280–287
- Ishaq S, Siau K, Harrison E (2017) Technological advances for improving adenoma detection rates: the changing face of colonoscopy. Dig Liver Dis 49:721–727
- Chin M, Karnes W, Jamal MM (2016) Use of the endocuff during routine colonoscopy examination improves adenoma detection: a meta-analysis. World J Gastroenterol 22:9642–9649
- Williet N, Tournier Q, Vernet C (2018) Effect of endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials. Endoscopy 50:846–860
- Triantafyllou K, Gkolfakis P, Tziatzios G (2019) Effect of endocuff use on colonoscopy outcomes: a systematic review and metaanalysis. World J Gastroenterol 25:1158–1170
- Jian HX, Feng BC, Zhang Y (2019) EndoCuff-assisted colonoscopy could improve adenoma detection rate: a meta-analysis of randomized controlled trials. J Dig Dis 20:578–588
- Patel HK, Chandrasekar VT, Srinivasan S (2020) Second-generation distal attachment cuff improves adenoma detection rate: meta-analysis of randomized controlled trials. Gastrointest Endosc S0016–5107(20):34847–34851
- 13. Floer M, Tschaikowski L, Schepke M (2021) Standard versus endocuff versus cap-assisted colonoscopy for adenoma detection:

a randomised controlled clinical trial. United Eur Gastroenterol J 9(4):443–450

- Marsano J, Johnson S, Yan S (2019) Comparison of colon adenoma detection rates using cap-assisted and endocuff-assisted colonoscopy: a randomized controlled trial. Endosc Int Open 7:E1585–E1591
- Rees CJ, Brand A, Ngu WS (2020) BowelScope: accuracy of detection using endocuff optimisation of mucosal abnormalities (the B-ADENOMA study): a multicentre, randomised controlled flexible sigmoidoscopy trial. Gut 69:1959–1965
- Rivero-Sánchez L, López Vicente J, Hernandez Villalba L (2019) Endocuff-assisted colonoscopy for surveillance of serrated polyposis syndrome: a multicenter randomized controlled trial. Endoscopy 51:637–645
- Aniwan S, Vanduangden K, Kerr SJ (2021) Linked color imaging, mucosal exposure device, their combination, and standard colonoscopy for adenoma detection: a randomized trial. Gastrointest Endosc. S0016–5107(21)01404–8
- Zorzi M, Hassan C, Battagello J (2021) Adenoma detection by endocuff-assisted versus standard colonoscopy in an organized screening program: the "ItaVision" randomized controlled trial. Endoscopy. doi: https://doi.org/10.1055/a-1379-6868
- Moher D, Liberati A, Tetzlaff J (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
- Higgins JPT, Altman DG, Gøtzsche PC (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928
- Bhattacharyya R, Chedgy F, Kandiah K (2017) Endocuff-assisted vs. standard colonoscopy in the fecal occult blood test-based UK Bowel Cancer Screening Programme (E-cap study): a randomized trial. Endoscopy 49:1043–1050
- 22. Biecker E, Floer M, Heinecke A (2015) Novel endocuff-assisted colonoscopy significantly increases the polyp detection rate: a randomized controlled trial. J Clin Gastroenterol 49:413–418
- Catalano MF, Khan NM, Lajin M (2017) Increase in adenoma detection rate (ADR) using endocuff (EC) assisted colonoscopy. Gastrointest Endosc 85(Suppl):AB495
- Cattau EL, Leal RJ, Ormseth EJ (2015) The effect of Endocuff<sup>TM</sup>assisted colonoscopy on adenoma detection rate: a randomized trial in community ambulatory surgical centers. Am J Gastroenterol 110(Suppl):S602
- Costa Santos M, Palmela C, Gouveia C (2019) Sessile serrated lesions detection with endocuff-assisted colonoscopyda randomized controlled trial. United Eur Gastroenterol J 7(9 Suppl):264–265
- 26. Floer M, Biecker E, Fitzlaff R (2014) Higher adenoma detection rates with endocuff-assisted colonoscopy—a randomized controlled multicenter trial. PLoS ONE 9:e114267
- González-Fernández C, Garcia-Rangel D, Aguilar-Olivos NE (2017) Higher adenoma detection rate with the endocuff: a randomized trial. Endoscopy 49:1061–1068
- Hass DJ, Jaffe C, Malangone L (2016) Endocuff (EC) increases adenoma detection rates on surveillance colonoscopy and improves efficiency of colonoscopy by shortening of withdrawal times. Gastroenterology 150(Suppl): S28
- Jacob A, Schafer A, Yong J (2019) Endocuff Vision-assisted colonoscopy: a randomized controlled trial. ANZ J Surg 89:E174–E178
- Karsenti D, Tharsis G, Perrot B (2020) Adenoma detection by endocuffassisted versus standard colonoscopy in routine practice: a clusterrandomised crossover trial. Gut 69:2159–2164
- Ngu WS, Bevan R, Tsiamoulos ZP (2019) Improved adenoma detection with endocuff Vision: the ADENOMA randomised controlled trial. Gut 68:280–288

- 32. Rex DK, Repici A, Gross SA (2018) High-definition colonoscopy versus endocuff versus endorings versus full-spectrum endoscopy for adenoma detection at colonoscopy: a multicenter randomized trial. Gastrointest Endosc 88:335-344.e2
- Rex DK, Slaven JE, Garcia J (2020) Endocuff Vision reduces inspection time without decreasing lesion detection in a randomized colonoscopy trial. Clin Gastroenterol Hepatol 18:158-162. e1
- van Doorn SC, van der Vlugt M, Depla ACTM (2017) Adenoma detection with endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial. Gut 66:438–445
- Vanduangden K, Aniwan S, Wisedopas N (2020) A comparison on the combination of linked color imaging and endocuff-assisted technologies and procedural innovation. Gastrointest Endosc 6(Suppl):AB45
- 36. von Figura G, Hasenöhrl M, Haller B (2020) Endocuff visionassisted vs.standard polyp resection in the colorectum (the EVASTA study): a prospective randomized study. Endoscopy 52:45–51
- Wada Y, Fukuda M, Ohtsuka K (2018) Efficacy of endocuffassisted colonoscopy in the detection of colorectal polyps. Endosc Int Open 6:E425–E431
- De Palma GD, Giglio MC, Bruzzese D (2018) Cap cuff-assisted colonoscopy versus standard colonoscopy for adenoma detection: a randomized back-to-back study. Gastrointest Endosc 87:232–240
- Triantafyllou K, Polymeros D, Apostolopoulos P (2017) Endocuff-assisted colonoscopy is associated with a lower adenoma miss rate: a multicenter randomized tandem study. Endoscopy 49:1051–1060

- Thayalasekaran S, Alkandari A, Varytimiadis L (2019) To cap/ cuff or ring: do distal attachment devices improve the adenoma detection? Expert Rev Gastroenterol Hepatol 13:119–127
- Facciorusso A, Del Prete V, Buccino V (2018) Full-spectrum versus standard colonoscopy for improving polyp detection rate: a systematic review and meta-analysis. J Gastroenterol Hepatol 33:340–346
- Facciorusso A, Buccino VR, Sacco R (2020) Endocuff-assisted versus cap-assisted colonoscopy in increasing adenoma detection rate. A meta-analysis. J Gastrointestin Liver Dis 29:415–420
- Facciorusso A, Mohan BP, Crinò SF (2021) Impact of endorings on colon adenoma detection rate: a meta-analysis of randomized trials. J Gastroenterol Hepatol 36:337–343
- 44. Aziz M, Haghbin H, Gangwani MK (2021) Efficacy of endocuff vision compared to first-generation endocuff in adenoma detection rate and polyp detection rate in high-definition colonoscopy: a systematic review and network meta-analysis. Endosc Int Open 9:E41–E50
- 45. Bretagne JF, Manfredi S, Piette C (2010) Yield of high-grade dysplasia based on polyp size detected at colonoscopy: a series of 2295 examinations following a positive fecal occult blood test in a population-based study. Dis Colon Rectum 53:339–345

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.